![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NEC Bio collaborate with AGC Biologics to support the manufacturing and development of NECVAX-NEO1, which is being evaluated in the early-stage for treatingf solid tumors.
Lead Product(s): NECVAX-NEO1
Therapeutic Area: Oncology Product Name: NECVAX-NEO1
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2024
Details:
First patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. The vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge AI capabilities to customize the treatment for each patient.
Lead Product(s): TG4050
Therapeutic Area: Oncology Product Name: TG4050
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Transgene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
These AI prediction platforms are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.
Lead Product(s): SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020